Effect of poly-L-arginine in inhibiting scrapie prion protein of cultured cells

Biological effect of poly-L-arginine (PLR), the linear homopolymer comprised of L-arginine, was investigated to determine the activity of suppressing prions. PLR decreased the level of scrapie prion protein (PrP^Sc) in cultured cells permanently infected with prions in a concentration-dependent manner. The PrP^Sc inhibition efficacy of PLR was greater than that of another prion-suppressant poly-L-lysine (PLK) in a molecular mass-dependent fashion. The effective concentration of PLR to inhibit prions was achieved safely below the cytotoxic concentrations, and overall cytotoxicity of PLR was similar to that of PLK. PLR did not alter the cellular prion protein (PrP^C) level and was unable to change the states of preformed recombinant PrP aggregates and PrP^Sc from prion-infected cells. These data eliminate the possibility that the action mechanism of PLR is through removal of PrP^C and pre-existing PrP^Sc. However, PLR formed complexes with plasminogen that stimulates prion propagation via conversion of PrP^C to the misfolded isoform, PrP^Sc. The plasminogen-PLR complex demonstrated the greater positive surface charge values than the similar complex with PLK, raising the possibility that PLR interferes with the role of cofactor for PrP^Sc generation better than PLK.

Perspectives On: Polymeric Drugs and Drug Delivery Systems

Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes, mellitus, rheumatoid arthritis, HIV infection, and drug addiction. Drug delivery technology is a multidisciplinary science involving the physical, biological, medicinal, pharmaceutical, biomedical engineering and biomaterial fields. Polymeric systems can deliver drugs directly to the intended site of action and can also improve efficacy while minimizing unwanted side effects elsewhere in the body, which often limit the long-term use of many drugs. In this article, some recent publications on several polymeric drug conjugates, gene delivery systems and polymer implants are addressed.

Recombinant polymers for cancer gene therapy: A minireview

A major challenge for successful cancer gene therapy is the development of safe and effective gene delivery vectors. Gene delivery vectors can be viral or nonviral. Among nonviral vectors various polymeric vectors have shown potential in gene delivery. However, much work needs to be done in order to correlate polymer structure with gene release at the target site and transfection efficiency. This article is a brief introduction into cancer gene therapy, barriers and methods for gene transfer with emphasis on the applications of recombinant polymers for cancer gene therapy.

Genetically engineered polymers: status and prospects for controlled release

Genetic engineering methodology has enabled the synthesis of protein-based polymers with precisely controlled structures. Protein-based polymers have well-defined molecular weights, monomer compositions, sequences and stereochemistries. The incorporation of tailor-made motifs at specified locations by recombinant techniques allows the formation of hydrogels, sensitivity to environmental stimuli, complexation with drugs and nucleic acids, biorecognition and biodegradation. Accordingly, a special interest has emerged for the use of protein-based polymers for controlled drug and gene delivery, tissue engineering and other biomedical applications. This article is a review of genetically engineered polymers, their physicochemical characteristics, synthetic strategies used to produce them and their biomedical applications with emphasis on controlled release.